Arash Rezazadeh Kalebasty, MD

Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.

While the findings from the most recent CARD study prove promising, it's the toxicity results that have one expert excited.